# CD19 t-haNK

Source: https://onco.cc/drugs/cd19-t-hank/  
OnCo record `cd19-t-hank` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CD19 t-haNK is an experimental cell therapy whose type is not stated from ImmunityBio in phase 2 trials for hodgkin lymphoma, aimed at CD19.

## Summary

CD19 t-haNK is a cell therapy whose type is not stated developed by ImmunityBio. Its target is CD19 (the sponsor names CD19). The sponsor states: CD19-targeted natural killer (haNK) cell therapy intended to bind CD19 on malignant B cells and drive immune-mediated cell death; studied in combination with the IL-15 superagonist N-803 (nogapendekin alfa inbakicept) and rituximab. ClinicalTrials.gov describes the intervention as: N-803 Subcutaneous (SQ): N-803 is a novel IL-15 superagonist immunotherapy administered subcutaneously. It is designed to enhance the proliferation and activation of natural killer (NK) cells and CD8+ T cells without stimulating regulatory. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT07125872, plans to enrol 20 participants with primary completion expected 2027-05-25. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: cell therapy (type not stated)
- Mechanism: CD19-targeted natural killer (haNK) cell therapy intended to bind CD19 on malignant B cells and drive immune-mediated cell death; studied in combination with the IL-15 superagonist N-803 (nogapendekin alfa inbakicept) and rituximab.

## Sources

- ClinicalTrials.gov: trials of CD19 t-haNK: https://clinicaltrials.gov/search?intr=CD19%20t-haNK
- Sponsor pipeline page: https://www.immunitybio.com/pipeline/

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- companies: [ImmunityBio](https://onco.cc/companies/immunitybio/)
- trials: [Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma](https://onco.cc/trials/nct07125872/)

---
JSON: https://onco.cc/api/v1/entities/cd19-t-hank.json